Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease

2012 ◽  
Vol 45 (3) ◽  
pp. 1051-1067 ◽  
Author(s):  
Natalie R.S. Goldberg ◽  
Victoria Fields ◽  
Lacey Pflibsen ◽  
Michael F. Salvatore ◽  
Charles K. Meshul
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
Motor Impairment

scholarly journals Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease

2011 ◽  
Vol 42 (3) ◽  
pp. 327-340 ◽  
Author(s):  
Veronica Francardo ◽  
Alessandra Recchia ◽  
Nataljia Popovic ◽  
Daniel Andersson ◽  
Hans Nissbrandt ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
Motor Impairment ◽  
6 Hydroxydopamine

scholarly journals Repositioning Doxycycline for treating Parkinson’s Disease: evidence from a pre-clinical mouse model

2022 ◽  
Author(s):  
Pietro La Vitola ◽  
Luisa Artioli ◽  
Milica Cerovic ◽  
Cristian Poletto ◽  
Letizia Dacomo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
Motor Impairment ◽  
Long Term Potentiation ◽  
Term Potentiation ◽  
Cognitive Behaviour ◽  
Effect Of Treatment ◽  
First Time

Abstract Background Parkinson’s disease remains orphan of valuable therapies capable to interfere with the disease pathogenesis despite the large number of symptomatic approaches adopted in clinical practice to manage this disease. Treatments simultaneously affecting α-synuclein (α-syn) oligomerization and neuroinflammation may counteract Parkinson’s disease. Recent data demonstrated that Doxycycline an antibiotic of the tetracycline class, can inhibit α-syn aggregation and exert anti-inflammatory activity. We herein investigate, for the first time, the potential therapeutic properties of Doxy in a human α-syn A53T transgenic Parkinson’s disease mouse model by the evaluation of behavioural, biochemical and histopathological parameters. Methods human α-syn A53T transgenic mice were treated with Doxycycline (10 mg/Kg daily ip) for 30 days, the effect of treatment on motor and cognitive behaviour impairment and daily live activity of mice were examined, successively immunocytochemical, electrophysiological and biochemical analysis of cerebral tissue was performed. Results Doxy treatment abolished cognitive and daily life activity deficiencies in A53T mice. The effect on cognitive functions was associated with neuroprotection, inhibition of α-syn oligomerization and gliosis both in the cortex and hippocampus. Doxy treatment restored hippocampal long-term potentiation in association with inhibition of pro-inflammatory cytokines expression. Moreover, Doxy ameliorated motor impairment and reduced striatal glial activation in A53T mice. Conclusions Our findings promote Doxy as a valuable multi-target therapeutic approach counteracting both symptoms and neuropathology in the complex scenario of α-synucleinopathies

Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

2017 ◽  
Vol 113 ◽  
pp. 110-123 ◽  
Author(s):  
Daniela Elgueta ◽  
María S. Aymerich ◽  
Francisco Contreras ◽  
Andro Montoya ◽  
Marta Celorrio ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
Dopamine Receptor ◽  
Motor Impairment

scholarly journals Dereplication of Components Coupled with HPLC-qTOF-MS in the Active Fraction of Humulus japonicus and It’s Protective Effects against Parkinson’s Disease Mouse Model

Molecules ◽  
2019 ◽  
Vol 24 (7) ◽  
pp. 1435 ◽  
Author(s):  
Hee Ju Lee ◽  
Basanta Dhodary ◽  
Ju Yong Lee ◽  
Jin-Pyo An ◽  
Young-Kyoung Ryu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
High Performance ◽  
Animal Studies ◽  
Motor Behavior ◽  
Motor Impairment ◽  
Protective Effects ◽  
Active Components ◽  
Humulus Japonicus

Humulus japonicus is an annual plant belonging to the Cannabacea family, and it has been traditionally used to treat pulmonary tuberculosis, dysentery, chronic colitis, and hypertension. We investigated the active components against Parkinson’s disease from H. japonicus fraction (HJF) using high performance liquid chromatography (HPLC) coupled with quadruple-time-of-flight mass spectroscopy (qTOF-MS) and NMR. Fourteen compounds were isolated from HJF, including one new compound, using HPLC-qTOF-MS and NMR. The major compounds of HJF were luteolin-7-O-glucoside and apigenin-7-O-glucoside, and there was approximately 12.57- and 9.68-folds increase in the contents of these flavonoids compared to those of the 70% EtOH extract. Apigenin and luteolin exhibited the strongest inhibitory effects on monoamine oxidase (MAO) B enzyme activity. In animal studies, limb-use behavior was significantly reduced by unilateral 6-OHDA lesion and ipsilateral rotations. These results indicated that oral administration of 300 mg/kg HJF resulted in the improvement of motor asymmetry and motor impairment in unilateral 6-OHDA-lesioned mice. HJF, including active components leads to an improvement of motor behavior in a Parkinson’s disease mouse model.

Sign in / Sign up

Export Citation Format

Share Document